Baxter International Inc. has appointed John Orloff, MD, as vice president and global head of research and development for Baxter BioScience, effective immediately. Orloff joins Baxter from Merck Serono Pharmaceuticals, where he served as global head of clinical development. He will be responsible for advancing the late-stage BioScience pipeline, enhancing the current R&D operating model, and pursuing additional innovative opportunities for the business.

Prior to his tenure at Merck Serono, Orloff spent approximately 10 years at Novartis, where he served in roles of increasing responsibility, including chief medical officer for global development. Earlier in his career, Dr. Orloff supported clinical development at Merck Research Labs and was previously a faculty member at the Yale University School of Medicine. His  expertise in bone biology contributed to marketing approvals for treatments for a range of bone disorders, and he has led programs across a diverse range of therapeutic areas, including immunology, neurology and oncology.

Source: Baxter International